Nivolumab Plus Ipilimumab in Thyroid Cancer

NCT03246958 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

53

Enrollment

OTHER

Sponsor class

Conditions

Thyroid Cancer

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]